ArticleBioorganic & medicinal chemistry2022
The 2022 Monkeypox outbreak: How the medicinal chemistry could help us?
Article in Bioorganic & medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Progress and prospects on vaccine development against monkeypox infection.Microbial pathogenesis · 2023Review
- Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox disease is a zoonosis that has the monkey virus (MPXV) as its etiologic agent, an enveloped double-stranded DNA virus that has caused some severe cases, leading to 3-6% fatality ratio. MPXV exhibits similar symptoms to those observed for Smallpox infection. Human-to-human transmission occurs via droplet respiratory particles and close contact with skin lesions of an infected person or recently contaminated objects. MPXV symptoms include fever, intense headache, back pain, myalgia, severe asthenia, lymphadenopathy, and skin eruption. The 2022 outbreak is growing, spreading over 75 countries/territories. Based on this, the MPXV outbreak was declared a "public health emergency of international concern" by WHO. In 2019, a vaccine-based modified attenuated vaccinia virus (Ankara strain) was approved for MPXV prevention. However, its availability remains limited. Besides, there are no approved or licensed drugs to treat MPXV currently. However, tecovirimat was licensed by the European Medicines Agency (EMA) to treat MPXV infections. Notwithstanding all these aspects and limitations associated with MPXV, How the medicinal chemistry could help us?
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.